Contagion Editorial Team

Nature Medicine published additional data on Vedanta Biosciences’ Clostridioides difficile investigational therapy, VE303, from its phase 2 trial.

The federal agency approved safety labeling changes to the prescribing information for Abrysvo (Pfizer) and Arexvy (GSK) RSV vaccines for seniors after data from clinical trials, reports to the Vaccine Adverse Event Reporting System (VAERS), and a postmarketing study.

From foodborne illness outbreaks to waterborne diseases and beyond, this year saw developments in the gastrointestinal infection space.

This week, concerns over mutated avian flu in a Louisiana patient, the potential of ibuzatrelvir for COVID-19 treatment, a comparison of ceftolozane-tazobactam and ceftazidime-avibactam for pneumonia treatment, and more.

Here are some of the bigger stories on this topic from this year.

A lot of Systane Lubricant Eye Drops Ultra PF has been voluntarily recalled by the manufacturer.

As the year is ending, here are some of the bigger stories Contagion covered on this topic.

As 2024 winds to a close, take a look back on some of the biggest stories Contagion was following around respiratory infections.

Vedanta Biosciences offered further insights on its completed phase 2 trial for its novel therapeutic, VE303.

The ongoing outbreak in the Democratic Republic of Congo is affecting mostly very young children, and has investigators searching for answers.

Here is a recap of the latest happenings during C diff awareness month.

Shionogi’s ensitrelvir demonstrated reduction of symptoms in phase 3 trial.

The clinical stage company, Recursion, dosed its first participant using a novel therapy that is not an antimicrobial.

Experts highlighted research showing that even mild COVID can result in cognitive impairment including brain fog and IQ decline, the FDA approved Pfizer's RSV vaccine for adults aged 18 to 59, E coli outbreak linked to McDonald's Quarter Pounders, and more.

This new indication for the bivalent respiratory syncytial virus prefusion F vaccine (Abrysvo) makes it the broadest currently available.

The late-breaking ID Week session reported on the once-weekly oral regimen being studied for use in people with HIV who are virologically suppressed.

At ID Week 2024, ViiV Healthcare reports its long-acting PrEP, cabotegravir (Apretude), is more than 99% effective.

This week, recent investigations link contaminated ice machines to Burkholderia multivorans infections, the hepatitis treatment market is projected to grow to USD 30.2 billion by 2032, 2020 guidelines recommend targeting specific AUC levels for optimizing vancomycin therapy, and more

People can now take the Healgen Rapid Check COVID-19/Flu A&B Antigen Test in their homes without a prescription.

The pharmaceutical company said there were no safety issues associated with the decision.

Enanta Pharmaceuticals says its investigational therapy, EDP-323, was found to be safe and efficacious against the respiratory virus.

Get caught up with the latest study information, feedback from people in the field, and news on the latest investigational therapies.

This week, a push for better care standards for C difficile, a survey shows low vaccination rates for respiratory viruses among Americans, Georgia achieves a reduction in chronic hepatitis C infections through collaborative efforts, and more.

The federal agency gave the nod to FluMist nasal spray to allows individuals to administer the vaccine themselves and as a caregivers to others.

This week, World AMR Congress interviews, Long COVID’s toll on the brain, e coli outbreak linked to lettuce, and more.

The platform, PfizerForAll, looks to enable telemedicine for certain health conditions and information about vaccination access.

A study on vancomycin treatment, new data on the investigational Pfizer C diff vaccine, how individual antibiotics are ranked by risk for C difficile infection, and more.

We have complied some of our news stories and interviews from the last week to offer information on the differences between clade I and clade 2 mpox, why WHO declaring the global emergency is significant, looking at mpox in the United States, and more.

The Africa CDC's declaration of the mpox outbreak as a Public Health Emergency of Continental Security, GIGA-2339's upcoming phase 1 trials for HBV, ActivePure Medical's air decontamination system's success in reducing MRSA and HAIs, and more this week from Contagion.

The companies’ study met 1 of their 2 primary immunogenicity objectives.